Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients

This study has been completed.
Sponsor:
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00275457
First received: January 11, 2006
Last updated: October 30, 2013
Last verified: October 2013

January 11, 2006
October 30, 2013
October 2002
April 2004   (final data collection date for primary outcome measure)
  • Mean change from baseline to week 6 on the RLSRS +
  • CGI-I responders (much and very much improved)
Mean change from baseline to week 6 on the RLSRS + CGI-I responders (much and very much improved)
Complete list of historical versions of study NCT00275457 on ClinicalTrials.gov Archive Site
RLRS responders, CGI, PGI responders, EPSS, QoL (SF-36) VAS severity of RLS
Same as current
Not Provided
Not Provided
 
Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients
A Randomised, Double-blind, Placebo-controlled Dose Titration Trial With 0.125-0.75 mg Pramipexole (Sifrol®) Orally to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome for 6 Weeks Followed by 46 Weeks Open-label or Double-blind Treatment Period

To evaluate safety and efficacy of pramipexole in the treatment of patients suffering from moderate to severe RLS over 6 weeks under double blinded conditions followed by a 46 week open label or double blind extension.

To evaluate safety and efficacy of pramipexole in the treatment of patients suffering from moderate to severe RLS over 6 weeks under double blinded conditions followed by a 46 weeks open label or double blind extension

Study Hypotheses:

Null hypothesis: No difference between pramipexole and placebo in RLSRS total score from baseline and no difference in the CGI-I responder rates at the end of the 6 weeks double-blind treatment.

Comparison(s):

Pramipexole vs. Placebo

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Restless Legs Syndrome
Drug: pramipexole
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
346
April 2004
April 2004   (final data collection date for primary outcome measure)

Inclusion criteria:

  1. Male or female out-patients aged 18-80
  2. Diagnosis of idiopathic RLS according to the Clinical RLS criteria of the International RLS Study Group. All of the four criteria must be present:

    • Irresistible urge to move usually associated with sensory complaints of the lower limbs
    • Motor restlessness
    • Worsening of the symptoms at rest with at least partial and temporary relief by activity
    • Increased severity in the evening or at night
  3. RLS rating scale for severity score > 15
  4. RLS symptoms present at least 2 to 3 days per week within in the last 3 months
  5. Written informed consent consistent with ICH/GCP and local legislation given prior to any study procedures
  6. Ability and willingness to comply with study treatment regimen and to attend study assessments

Exclusion criteria:

  1. Women of childbearing potential, who do not use adequate protection such as barrier protection, intrauterine device, or hormonal (oral or subcutaneous) contraception or postmenopausal women less than 6 months after last menses, surgically sterilised, oophorectomised or hysterectomised less than 3 months after operation and not using adequate protection or women neither using adequate protection nor being postmenopausal and their partner is not sterilised at least 6 months post operation or does not use condom, or any women not having negative serum pregnancy test at screening
  2. Males not using an adequate form of contraception (condom, sterilisation at least 6 months post operation)
  3. Patients who are breastfeeding
  4. Concomitant or previous pharmacologically therapy of RLS as follows:

    • Any intake of levodopa within 5 days prior to baseline visit (V2)
    • Any intake of dopamine agonists within 14 days prior to baseline visit (V2)
    • History of any intake of pramipexole
  5. Current (less than 14 days before treatment with trial medication or concomitant) treatment with medication or dietary supplements, which could significantly influence RLS symptoms - withdrawal symptoms caused by stopping any of the drugs above
  6. Confirmed diagnose of diabetes mellitus requiring insulin therapy
  7. Clinically significant renal disease or creatinine higher than upper limit of normal (ULN) at screening
  8. Clinically significant hepatic disease or sGPT > 2 times the upper limit of normal range at screening
  9. Clinical or laboratory signs of microcytic anaemia at the investigators discretion
  10. Any of the following lab results at screening:

    • Hb or erythrocyte count below lower limit of normal (LLN)
    • Basal TSH, T3 or T4 clinically significantly (at the investigator's discretion) out of normal range at screening (if not caused by substitution therapy according the investigator's opinion)
  11. Other clinically significant metabolic-endocrine, haematological, gastro-intestinal disease or pulmonary disease. Poorly controlled cardiovascular disease
  12. History or clinical signs of peripheral neuropathy (PNP) of any origin in physical, neurological examination, myelopathy or multiple sclerosis or any other neurological disease, with potential to secondarily cause RLS symptoms
  13. Presence of any other sleep disorder, such as, REM sleep behaviour disorder, narcolepsy or sleep apnoea syndrome
  14. History of Schizophrenia or any psychotic disorder, history of mental disorders due to a general medical condition or any present axis I psychiatric disorder according DSM IV requiring any medical therapy or history of or alcohol abuse or drug addiction within the last 2 years before screening
  15. Participation in a drug study within two months prior to the start of this study
  16. History of or clinical signs for any form of epilepsy or seizures apart from fever related seizures in early childhood
  17. History of or clinical signs of malign neoplasm
  18. Patients on a shift-work-schedule, or who are otherwise unable to follow a regular sleep-wake cycle enabling use of study medication at times indicated
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Austria,   Netherlands,   Sweden,   Germany,   Norway
 
NCT00275457
248.520
Not Provided
Not Provided
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Study Coordinator B.I. Pharma GmbH & Co. KG
Boehringer Ingelheim
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP